Neutrophils can either aid pathogen clearance or drive tissue damage. The study team tested whether transcriptional programs tied to neutrophil maturation distinguish two pulmonary infections with heavy neutrophil involvement: COVID-19 and active tuberculosis. They report that maturation-associated transcription represents the most consistently reproduced axis separating the two diseases, with distinct patterns in maturation markers and genes linked to neutrophil extracellular trap (NET) biology.
The investigators pooled six publicly available whole-blood bulk RNA-sequencing datasets—three from COVID-19 cohorts and three from active TB cohorts. They analyzed a curated panel of 770 genes that covered activation, degranulation, NET formation, chemotaxis, cell surface receptors, and maturation. To reduce study-associated batch effects they applied ComBat-Seq. Differential expression was then assessed with DESeq2 against disease-appropriate controls. The source did not report additional experimental details such as individual cohort sizes, patient demographics, or sampling timepoints.
Data indicated that most genes shifted in the same direction in both infections, but a substantial subset differed in response magnitude. Specifically, 348 genes—45.2% of the panel—showed significant differences in response magnitude between COVID-19 and TB. Of those, 159 genes exhibited stronger responses in COVID-19 while 189 genes showed stronger responses in TB. These quantitative differences framed downstream interpretation of maturation and functional transcriptional modules.
In COVID-19 samples the study team observed reduced expression of canonical maturation markers CD10 (MME) and CD16 (FCGR3A). At the same time, granule-cargo and NET-associated genes such as MPO and ELANE were elevated. The authors interpret this pattern as consistent with an increased contribution from immature neutrophil populations arising from emergency granulopoiesis. By contrast, TB samples displayed higher expression of maturation-associated transcripts, multiple receptor genes, oxidative pathway-related genes, and recruitment-related signals—features consistent with a relatively mature, receptor-competent neutrophil transcriptional signature.
The study team cross-checked signatures in independent cohorts: a COVID-19 Ward cohort and a pulmonary TB cohort. Directional agreement for the maturation and NET-associated signatures was high—100% concordance in maturation signals and 90% concordance for NET-associated signals. Chemotaxis-related genes and select receptor and degranulation transcripts showed weaker reproducibility across cohorts, indicating heterogeneity in those axes. The source did not provide full lists of the independently validated genes beyond the concordance metrics cited.
These transcriptional differences point to measurable axes that could be developed as candidate biomarkers linking neutrophil states to clinical outcomes. The authors suggested that distinguishing immature, NET-prone neutrophil responses from mature, receptor-competent signatures may inform host-directed therapies that seek to preserve antimicrobial function while limiting immunopathology. The source did not report prospective biomarker validation, clinical performance metrics, or therapeutic intervention testing—those remain to be evaluated in follow-up studies.
The integrated analysis is informative but leaves several concrete questions unresolved. The source did not report patient-level clinical characteristics, timing of sampling relative to disease course, or cohort sizes, limiting assessment of confounding by disease severity or duration. It remains unknown how the identified transcriptional states map to functional neutrophil behaviors in vivo or to specific clinical outcomes such as respiratory failure or treatment response. The authors note these signatures as candidate biomarkers; prospective validation, mechanistic linkage to neutrophil function, and testing in interventional trials are explicit next steps documented by the team.
The article provides a clear comparative transcriptional snapshot. What it does not provide are cohort demographics, longitudinal sampling data, or direct clinical correlations—data that will be necessary if these signatures are to guide bedside decisions or host-directed therapies.